Events

­

Quark will present at Eurotides 2015, Maritim proArte Hotel, Berlin, Germany ,16-18 Nov 2015

August 23rd, 2015|

http://www.informa-ls.com/event/eurotides2015

Quark will present at 2015 American Transplant Congress, May 5, 2015

April 5th, 2015|

Relationship Between Delayed Graft Function (DGF) Severity and Predicted DGF Risk

E. Squiers,1 B. Irish,1 D. Odenheimer,1 S. Erlich,1 J. Grinyo, S. Feng, On Behalf of Quark DGF Study Investigators.

1Quark, Fremont
2UCSF, SF
3U of Barcelona, BCN, Spain.

Meeting: 2015 American Transplant Congress

Abstract number: 448

Keywords: Cadaveric organs, Graft function, Kidney transplantation, Outcome

 

http://www.atcmeetingabstracts.com/abstract/relationship-between-delayed-graft-function-dgf-severity-and-predicted-dgf-risk/

Quark will present at TIDES 2015, at the Town and Country Hotel in San Diego, CA, May 3-6, 2015

April 3rd, 2015|

Results of a Large Phase 2 siRNA Study: Target Expression Translates to Therapeutic Outcomes
Results of large (N=326) P2 study showed QPI-1002, a systemically administered siRNA targeting p53, significantly reduced the clinical endpoint of severity of delayed graft function post-transplant, especially in kidneys from older donors (p<0.016); which are known to have increased p53. A P3 […]

Quark will present at The 7th GTC Ocular Disease Drug Discovery Conference. San Diego, CA. March 18-19, 2015.

February 18th, 2015|

A Synthetic Chemically Modified siRNA Targeting Caspase 2 as a Therapeutic Agent for Ocular Neuroprotection

https://www.gtcbio.com/conferences/ocular-diseases-drug-discovery-speakers

Quark will present at Targeting Ocular Disorders. Boston, MA. October 6-7, 2014

September 6th, 2014|

A Synthetic Chemically Modified siRNA Targeting Caspase-2 as a Therapeutic Agent for Ocular europrotection
Elena Feinstein, M.D., Ph.D., CSO, Quark Pharmaceuticals
Caspase-2 is a pro-apoptotic gene specifically expressed and activated in retinal
ganglion cells following acute optic nerve injury or intraocular pressure increase.
Intravitreal administration of QPI1007 (a syntehticsiRNA targeting caspase-2)
demonstrated local RNA interference, lack of inflammatory effects and […]

Quark will present at 2014 World Transplant Congress July 26-31st 2014

July 26th, 2014|

Treatment with QPI-1002, a Short Interfering (SI) RNA for the

Prophylaxis of Delayed Graft Function. V. Peddi,1 L. Ratner,2 M.

Cooper,2 O. Gaber,2 S. Feng,2 P. Tso,2 V. Bowers,2 R. Naraghi,2 K. Budde,2

Polinsky,3 E. Squiers,3 S. Erlich,3 Study Investigators Group.2 1CPMC,

San Francisco, CA; 2Multiple Institutions; 3Quark Pharmaceuticals,

Fremont.

Introduction: Delayed graft function (DGF) can adversely affect deceased donor

renal transplant […]

Quark will present at TIDES: Oligonucleotide Therapeutics Discovery. Providence, RI, May 12-15, 2014.

April 12th, 2014|

Use of siRNA for Treatment of Inner Ear Diseases.

Quark Pharmaceuticals to Participate in IBC’s Oligonucleotide Therapeutics: From Concept to Implementation Conference

August 3rd, 2009|

Fremont, CA – August 3, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will participate in multiple roles at IBC’s Oligonucleotide Therapeutics: from Concept to Implementation Conference. The conference will take place August 3-5, 2009 in […]

Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3

May 11th, 2009|

Fremont, CA – May 11, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, “PF-04523655 (REDD14NP), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation,” at […]

Quark Pharmaceuticals Presents at American Society for Pharmacology and Experimental Therapeutics Annual Meeting

April 20th, 2009|

Fremont, CA – April 20, 2009 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will give a presentation on Tuesday, April 21 at this year’s American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting, which […]